Key Takeaways
- Researchers from Linköping University found that HIV overactivates the immune system, despite antiviral treatments.
- A medication called anifrolumab, used for lupus, may restore immune cell function in people with HIV.
- Further studies are needed to explore the combined use of this drug with existing antiviral treatments for improved health outcomes.
Impact of HIV on the Immune System
HIV is known to compromise the immune system by overactivating it, even in individuals receiving effective antiviral treatment. Researchers from Linköping University conducted a study that indicates this overactivation leads to premature aging of the immune system despite the presence of antiviral medications, which effectively limit the viral load in blood and slow AIDS progression.
In a healthy immune response to viral infections, the body activates type I interferon, a crucial protein that provides initial protection against viruses. Ideally, after combating an infection, the interferon levels drop. However, in cases of HIV, research reveals that the virus exploits this mechanism, leading to chronic immune activation that facilitates its spread within the body.
Cecilia Svanberg, the study’s lead author, noted that although type I interferon is initially protective during the infection phase, its prolonged activation can backfire. “If the interferon is chronically activated, an overactivation of the immune system will instead facilitate the spread of HIV in the body,” she explained.
As the immune system remains in a chronic state of activation, various immune cells—including dendritic cells and T cells—become exhausted and less effective. The researchers found that this exhaustion occurs specifically when dendritic cells interact with T cells, suggesting a potential path for restoring immune function.
To test this hypothesis, the researchers applied an existing medication, anifrolumab, which blocks type I interferon and is typically used to treat systemic lupus erythematosus (SLE). Their experiments showed that when treated with this medication, the immune cells returned to functioning as if HIV was absent.
Further research in animal models with HIV-like infections has also demonstrated that treatments involving anifrolumab led to decreased viral loads and improved overall health for the subjects involved. Marie Larsson, a professor of virology at Linköping University, emphasized the potential of combining anifrolumab with standard antiviral treatments to enhance the health and well-being of individuals living with HIV.
While the findings are promising, researchers recognize the need for further investigation to assess the effectiveness and safety of such treatment combinations in human subjects. The study received funding from the Swedish Research Council and Region Östergötland, contributing to the growing understanding of how to optimize treatment regimens for people living with HIV.
This groundbreaking research highlights the adaptability of antiviral treatments and their potential to be repurposed for improving immune function in patients, heralding a new avenue in the fight against HIV.
The content above is a summary. For more details, see the source article.